When Christina was diagnosed with Glioblastoma (GBM) in February 2020, our world flipped upside down. The idea of losing my wife to cancer became a terrifying reality. Emotions were chaotic, and thinking clearly felt impossible. Our first instinct was to learn everything we could about this disease. Information came at us fast and from every direction. The most shocking fact? GBM is the most common primary malignant brain tumor in adults, with a median survival of only 15 months (1). Treatment usually begins with a biopsy and tumor removal , followed by radiotherapy and chemotherapy with alkylating agents . Christina received temozolomide (TMZ) , and later bevacizumab , a monoclonal antibody that blocks the tumor’s blood supply (10). I’ve decided to write a series of posts documenting what I’ve learned about GBM and my ideas—naïve though they may be—about how we might improve outcomes for patients, from the perspective of a chemist. During my chemistry career (1984–1998), I worked on ...